Your browser is no longer supported. Please, upgrade your browser.
ARNA Arena Pharmaceuticals, Inc. monthly Stock Chart
ARNA [NASD]
Arena Pharmaceuticals, Inc.
Index- P/E- EPS (ttm)-0.43 Insider Own0.59% Shs Outstand242.88M Perf Week7.28%
Market Cap393.46M Forward P/E- EPS next Y-0.32 Insider Trans0.00% Shs Float241.60M Perf Month-9.50%
Income-105.20M PEG- EPS next Q-0.10 Inst Own53.10% Short Float6.69% Perf Quarter5.88%
Sales35.90M P/S10.96 EPS this Y-62.90% Inst Trans-1.99% Short Ratio7.94 Perf Half Y-23.58%
Book/sh0.15 P/B10.80 EPS next Y5.90% ROA-37.80% Target Price3.00 Perf Year-59.35%
Cash/sh- P/C- EPS next 5Y- ROE-150.00% 52W Range1.30 - 5.12 Perf YTD-14.74%
Dividend- P/FCF- EPS past 5Y17.00% ROI-84.70% 52W High-68.36% Beta-0.53
Dividend %- Quick Ratio3.00 Sales past 5Y18.20% Gross Margin63.30% 52W Low24.62% ATR0.08
Employees228 Current Ratio3.20 Sales Q/Q-20.30% Oper. Margin- RSI (14)47.33 Volatility4.20% 5.18%
OptionableYes Debt/Eq1.80 EPS Q/Q13.90% Profit Margin- Rel Volume0.50 Prev Close1.59
ShortableYes LT Debt/Eq1.72 EarningsMay 09 AMC Payout- Avg Volume2.03M Price1.62
Recom2.70 SMA201.74% SMA50-7.08% SMA200-18.13% Volume1,008,561 Change1.89%
Mar-01-16Reiterated RBC Capital Mkts Sector Perform $2 → $1.50
Nov-11-15Reiterated RBC Capital Mkts Sector Perform $5 → $2
Oct-28-15Reiterated WallachBeth Buy $6 → $4
May-12-15Reiterated WallachBeth Buy $8 → $6
Jan-23-15Initiated RBC Capital Mkts Sector Perform $5
Aug-07-14Reiterated WallachBeth Buy $9 → $8
Nov-15-13Initiated WallachBeth Buy $9
Oct-03-13Initiated Cowen Market Perform $4.50
Oct-25-10Reiterated Barclays Capital Underweight $3 → $2
Sep-20-10Reiterated UBS Neutral $7 → $2
Sep-17-10Downgrade Davenport Buy → Neutral
Sep-14-10Downgrade Barclays Capital Equal Weight → Underweight $4 → $3
Aug-23-10Reiterated UBS Neutral $3.50 → $7
Jul-16-10Downgrade Rodman & Renshaw Mkt Perform → Mkt Underperform $1
Jul-02-10Reiterated UBS Buy $40 → $38
Feb-04-10Upgrade Rodman & Renshaw Mkt Underperform → Mkt Perform
Dec-17-09Initiated Jefferies & Co Hold $4
Sep-21-09Downgrade Leerink Swann Outperform → Mkt Perform $6
Sep-18-09Downgrade Rodman & Renshaw Mkt Perform → Mkt Underperform $3
Sep-15-09Downgrade Rodman & Renshaw Mkt Outperform → Mkt Perform
May-26-16 07:10PM  ETFs with exposure to Arena Pharmaceuticals, Inc. : May 26, 2016
May-23-16 01:05PM  Drawing Biopharma Concepts With A Crayon at Motley Fool
May-18-16 01:04PM  ARENA PHARMACEUTICALS INC Financials
May-16-16 06:40PM  ETFs with exposure to Arena Pharmaceuticals, Inc. : May 16, 2016
May-13-16 10:21AM  Arena Pharmaceuticals, Inc. :ARNA-US: Earnings Analysis: Q1, 2016 By the Numbers
May-10-16 08:27AM  Arena's (ARNA) Q1 Loss Narrower but Revenues Fall Short
07:30AM  Boston drug firm's shares slump due to job cuts, cash shortage at American City Business Journals
12:57AM  Edited Transcript of ARNA earnings conference call or presentation 9-May-16 9:00pm GMT
May-09-16 05:14PM  ARENA PHARMACEUTICALS INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and
05:07PM  Arena Pharmaceuticals reports 1Q loss
04:05PM  Arena Pharmaceuticals Reports First Quarter 2016 Financial Results and Provides Corporate Update PR Newswire
04:05PM  Arena Pharmaceuticals Announces Appointment of Amit D. Munshi as President and Chief Executive Officer PR Newswire
07:07AM  Q1 2016 Arena Pharmaceuticals Inc Earnings Release - After Market Close CCBN
May-06-16 03:42PM  Arena Pharmaceuticals' Shares Slid 13% in April: Can the Stock Bounce Back? at Motley Fool
09:43AM  Drug Stocks Reporting Early Next Week: TEVA, ARNA & More Zacks
May-04-16 08:07AM  Arena (ARNA) Q1 Earnings: What's in Store for the Stock? Zacks
May-02-16 04:05PM  Arena Pharmaceuticals to Host First Quarter 2016 Financial Results and Corporate Update Conference Call and Webcast on Monday, May 9 PR Newswire
08:53AM  Arena Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : ARNA-US : May 2, 2016 at Capital Cube
Apr-21-16 07:46AM  New Strong Sell Stocks for April 21st Zacks
Apr-17-16 10:04AM  How Much Potential Does Saxenda Hold for Novo?
Apr-13-16 01:00PM  Arena (ARNA) Gains, Pain Drug Positive in Early Stage Study
09:52AM  New Strong Sell Stocks for April 13th
Apr-12-16 01:33PM  ARENA PHARMACEUTICALS INC Files SEC form 8-K, Other Events
01:21PM  Arena Pharma (ARNA) Stock Advancing on Favorable Trial Results at TheStreet
08:00AM  Arena Pharmaceuticals Reports Favorable Results from Phase 1b Multiple-Ascending Dose Clinical Trial of APD371 PR Newswire
Apr-08-16 05:25PM  Arena Pharmaceuticals, Inc. Rides Celgene's Coattails to Big Gains in March at Motley Fool -5.00%
Mar-28-16 08:33AM  Arena Pharmaceuticals Extends Its Winning Streak (ARNA, CELG) at Investopedia
08:02AM  Analyst Report; Expected FDA Decisions Around the Corner Accesswire
Mar-22-16 11:31AM  Stocks to Watch for Tuesday 3/22/2016, If You Choose Accesswire +8.99%
Mar-21-16 01:35PM  Why Arena Pharmaceuticals Surged 10% Last Week (ARNA) at Investopedia +7.88%
08:15AM  Arena Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : ARNA-US : March 21, 2016
06:07AM  ARENA PHARMACEUTICALS INC Files SEC form 8-K, Regulation FD Disclosure
Mar-16-16 12:19PM  Hedge Funds Think These 4 Marijuana Stocks Are Pretty Dope at Insider Monkey
Mar-15-16 10:15AM  Why Investors Should Sell These Biotech Stocks & Buy Gilead Instead -5.88%
Mar-14-16 05:45PM  How Speculation Drives Investment in Arena Pharmaceuticals (ARNA) at Investopedia
09:30AM  The Zacks Analyst Blog Highlights: Gilead Sciences, Celgene, Amgen, Regeneron Pharmaceuticals and Arena Pharmaceuticals
Mar-11-16 09:37AM  Biotech Investing Guide: 3 Stocks to Buy and 3 to Avoid
Mar-08-16 09:56AM  New Strong Sell Stocks for March 8th -5.66%
06:36AM  Analyzing Arena Pharma's Return on Equity (ARNA, IMGN) at Investopedia
Mar-04-16 09:13AM  New Strong Sell Stocks for March 4th
Mar-01-16 09:30AM  Arena's (ARNA) Q4 Loss Narrower but Revenues Fall Short
Feb-29-16 11:50PM  Edited Transcript of ARNA earnings conference call or presentation 29-Feb-16 10:00pm GMT
05:21PM  ARENA PHARMACEUTICALS INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and
04:33PM  Arena Pharmaceuticals reports 4Q loss
04:19PM  Arena Pharmaceuticals (ARNA) Stock Edges Lower in After-Hours Trading on Q4 Results at TheStreet
04:00PM  Arena Pharmaceuticals Reports Fourth Quarter and Full Year 2015 Financial Results and Provides Corporate Update PR Newswire
07:07AM  Q4 2015 Arena Pharmaceuticals Inc Earnings Release - After Market Close
Feb-26-16 01:20PM  Will Arena (ARNA) Post a Narrower-than-Expected 4Q Loss?
Feb-23-16 08:00AM  Arena Pharmaceuticals to Host Fourth Quarter and Full Year 2015 Financial Results and Corporate Update Conference Call and Webcast on Monday, February 29 PR Newswire -9.88%
Feb-16-16 09:00AM  Small Cap Acquisition Candidates See Increased Investor Interest Accesswire
Feb-09-16 10:23AM  Here's Why Arena Pharmaceuticals Lost 17% of Its Value in January at Motley Fool
Feb-08-16 08:00AM  Biotechnology Stocks Technical Review -- MannKind, Array BioPharma, Arena Pharma, and Chimerix Accesswire
Jan-20-16 03:33PM  Former US president Jimmy Carter Says His Brain Cancer Has Disappeared Accesswire +7.74%
Jan-19-16 10:17AM  Bioelectronic-Medicine Leader Endonovo Therapeutics, Inc. Begins 2016 on a Strong Note Accesswire -6.06%
Jan-13-16 04:25PM  Arena, Boehringer Ingelheim Ink Deal, Schizophrenia in Focus
Jan-12-16 05:19PM  [$$] Arena Pharma Shares Rise on Collaboration Pact With Boehringer at The Wall Street Journal +8.28%
04:55PM  ARENA PHARMACEUTICALS INC Files SEC form 8-K, Other Events
04:05PM  Boehringer Ingelheim and Arena Pharmaceuticals Collaborate to Advance Research in Schizophrenia PR Newswire
Jan-07-16 01:02PM  This Company is Up +400% in a Month Accesswire -6.86%
12:04PM  Arena Pharmaceuticals Ends 2015 On a Sour Note: Can It Recover in 2016? at Motley Fool
08:15AM  CEL-SCI Corp (CVM) Shows Strength: Stock Moves Up 8.3%
08:00AM  Arena Pharmaceuticals to Present at the 34th Annual J.P. Morgan Healthcare Conference PR Newswire
Jan-06-16 08:00AM  Biotechnology Equity Picks - Arena Pharma, uniQure, Cytokinetics, and Curis Accesswire -5.91%
Jan-05-16 05:05PM  Teva/Active Biotech Halt High Doses of Laquinimod for MS
01:50PM  Pfizer & Merck KGaA Partner with Syndax for Ovarian Cancer
Jan-04-16 08:05AM  Pluristem Therapeutics (PSTI) in Focus: Stock Rises 14.1%
Dec-30-15 10:23AM  The Worst 3 Biotech Stocks for 2016 at Motley Fool
08:02AM  Arena Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : December 30, 2015
Dec-29-15 09:30AM  New Strong Buy Stocks for December 29th
Dec-23-15 08:00AM  Biotechnology Equities Update -- Arena Pharma, Compugen, ChemoCentryx, and Concert Pharma Accesswire
Dec-22-15 09:30AM  New Strong Buy Stocks for December 22nd
Dec-21-15 10:10AM  Arena Pharmaceuticals, Inc. Earnings Analysis: Q3, 2015 By the Numbers +6.84%
08:00AM  Technical Report on Biotechnology Stocks -- Arena Pharma, Cara Therapeutics, Corcept Therapeutics, and Ignyta Accesswire
Dec-18-15 09:30AM  New Strong Buy Stocks for December 18th
Dec-16-15 08:00AM  Biotechnology Equities Scrutiny -- Arena Pharma, Lion Biotechnologies, Bellicum Pharma, and ANI Pharma Accesswire +5.59%
Dec-14-15 08:39AM  Why Arena Pharmaceuticals (ARNA) Could Beat Earnings Estimates Again
Dec-08-15 01:12PM  Orexigen Therapeutics' Stock Dropped 28% in November: Can It Recover? at Motley Fool
Dec-07-15 01:11PM  Arena Pharmaceuticals, Inc. Value Analysis (NASDAQ:ARNA) : December 7, 2015 -7.73%
12:29PM  Bluebird Bio Crashes After Clinical Trial Update
09:37AM  Arena Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : December 7, 2015
09:30AM  New Strong Buy Stocks for December 7th
Dec-05-15 10:15AM  Top 6 BioPharma Movers of the Week at 24/7 Wall St.
Dec-04-15 04:57PM  Orexigen Therapeutics, Inc.'s Stock Loses Weight on Downgrade at Motley Fool -5.91%
02:08PM  Why Arena Pharmaceuticals, Inc. Bulked Up in November at Motley Fool
Dec-03-15 09:30AM  New Strong Buy Stocks for December 3rd
07:00AM  Why Axovant Sciences Skyrocketed 56% in November at Motley Fool
Dec-02-15 03:20PM  Zafgen Plunges On Death In Obesity-Drug Trial at Investor's Business Daily
11:22AM  Can the Rally in Arena Pharmaceuticals (ARNA) Shares Continue?
Dec-01-15 05:05PM  ARENA PHARMACEUTICALS INC Files SEC form 8-K, Other Events -5.44%
04:32PM  Arena (ARNA)/Eisai's Belviq XR NDA Accepted for Review
11:06AM  Here's Why Arena Pharmaceuticals' Stock Briefly Spiked Today at Motley Fool
09:30AM  New Strong Buy Stocks for December 1st
08:00AM  Eisai and Arena Pharmaceuticals Announce Completion of Enrollment in BELVIQ® (lorcaserin HCI) CAMELLIA-TIMI 61 Study PR Newswire
Nov-30-15 07:40PM  Why Ambarella, Arena Pharmaceuticals, and ITC Holdings Jumped Today at Motley Fool +11.16%
01:35PM  Arena Pharma Soars on FDA Approval
08:37AM  How Arena Pharma (ARNA) Stock Stands Out in a Strong Industry
08:00AM  Eisai and Arena Pharmaceuticals Announce FDA Acceptance of New Drug Application for Extended Release Formulation of Lorcaserin PR Newswire
Nov-27-15 09:05AM  Nextera Energy Partners LP (NEP): Are Hedge Funds Right About This Stock? at Insider Monkey
Nov-25-15 05:35PM  Drugmakers drop weight
Nov-24-15 12:07PM  Is Smart Money Losing Interest in Uniqure NV (QURE)? at Insider Monkey
Arena Pharmaceuticals, Inc., a biopharmaceutical company, discovers, develops, and commercializes novel drugs that target G protein-coupled receptors to address unmet medical needs in the United States and South Korea. The company offers BELVIQ, a drug used to treat chronic weight management in adults. It is also developing a portfolio of programs in various therapeutic areas, including cardiovascular, central nervous system, and metabolic diseases. Its products under development include APD334, a modulator of the sphingosine 1-phosphate subtype 1 receptor for the treatment of a various autoimmune diseases, which is in Phase II clinical trials; and Ralinepag that is in Phase II clinical trials for the treatment of pulmonary arterial hypertension. The company's products under development also comprise APD371, an agonist of the cannabinoid-2 receptor that is in Phase I clinical trials for the treatment of pain; Nelotanserin, which is in Phase II clinical trials for the treatment of dementia-associated psychosis; Temanogrel, which is in Phase I clinical trials for thrombotic diseases; and Undisclosed Orphan GPCR that is in pre-clinical development for central nervous system indications. In addition, it manufactures drug products under a toll manufacturing agreement for Siegfried AG. Arena Pharmaceuticals, Inc. has collaboration with Boehringer Ingelheim International GmbH. The company was founded in 1997 and is based in San Diego, California.